Authors: de Jonge, MJA Sparreboom, A Planting, AST van der Burg, MEL de Boer-Dennert, MM ter Steeg, J Jacques, C Verweij, J

Citation: Mja. De Jonge et al., Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors, J CL ONCOL, 18(1), 2000, pp. 187-194

Authors: de Jonge, MJA Verweij, J de Bruijn, P Brouwer, E Mathijssen, RHJ van Alphen, RJ de Boer-Dennert, MM Vernillet, L Jacques, C Sparreboom, A

Citation: Mja. De Jonge et al., Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin, J CL ONCOL, 18(1), 2000, pp. 195-203

Authors: de Jonge, MJA Verweij, J Planting, AST van der Burg, MEL Stoter, G de Boer-Dennert, MM de Bruijn, P Brouwer, E Vernillet, L Sparreboom, A

Citation: Mja. De Jonge et al., Drug-administration sequence does not change pharmacodynamics and kineticsof irinotecan and cisplatin, CLIN CANC R, 5(8), 1999, pp. 2012-2017

Authors: van Zuylen, L Schellens, JHM Goey, SH Pronk, LC de Boer-Dennert, MM Loos, WJ Ma, JG Stoter, G Verweij, J

Citation: L. Van Zuylen et al., Phase I and pharmacologic study of the arotinoid Ro 40-8757 in combinationwith cisplatin and etoposide in patients with non-small cell lung cancer, ANTI-CANC D, 10(4), 1999, pp. 361-368